Metastatic disease was reported in 0% to 33% of PGL patients with SDHA mutations, although these reports included few patients (n = 4‐34).31, 32, 33, 34, 35, 36 GISTs and pituitary adenomas were reported in a small subset of patients.24, 31, 32, 37, 38 In a large pediatric GIST study of Boikos et al, a SDHA mutation, germline or somatic, was the most common molecular subtype39 Neuroblastoma was reported in one SDHA mutation carrier where it was possible to confirm loss of heterozygosity (LoH) in tumor tissue.38 Here, SDHA is linked to pituitary gland adenoma.